Case series:BCMA-CD38 bispecific CAR-T cells

2 trials

Sponsors

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The Second Clinical Medical College, Yangtze University, Jingzhou Central Hospital

Conditions

Relapsed or Refractory Multiple Myeloma

Phase 1

BCMA-CD38 Bispecific Chimeric Antigen Receptor (CAR)-Modified T Cells in the Treatment of Relapsed or Refractory Multiple Myeloma

RecruitingChiCTR1800018143

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRelapsed or Refractory Multiple Myeloma

Start: 2018-09-01Updated: 2018-09-03

Clinical Study for the Efficacy and Safety of BCMA-CD38 Bispecific CAR-T cells in Relapsed and Refractory Multiply Myeloma

RecruitingChiCTR1900026286

The Second Clinical Medical College, Yangtze University, Jingzhou Central HospitalRelapsed or Refractory Multiple Myeloma

Start: 2018-05-08Updated: 2019-09-30

Related Papers

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Journal of Experimental & Clinical Cancer Research2022-01-0386 citations

Infectious Complications Following Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancy

Blood2021-11-05

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

Journal of Hematology & Oncology2021-10-09210 citations

[Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days].

PubMed2021-09-145 citations

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Blood2019-11-1382 citations

S826 IMPROVED EFFICACY AND SAFETY OF A DUAL‐TARGET CAR‐T CELL THERAPY TARGETING BCMA AND CD38 FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM A PHASE I STUDY

HemaSphere2019-06-0110 citations

PS1222 IL‐6 ASSOCIATED WITH GRADING OF CYTOKINE RELEASE SYNDROME AND MANAGEMENT TIME OF TOCILIZUMAB AFTER CAR‐T CELL THERAPY

HemaSphere2019-06-01